Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

MLA

Finkel, Richard S., et al. “Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).” Journal of Neuromuscular Diseases, vol. 10, no. 3, Nov. 2023, pp. 389–404. EBSCOhost, https://doi.org/10.3233/JND-221560.

APA

Finkel, R. S., Darras, B. T., Mendell, J. R., Day, J. W., Kuntz, N. L., Connolly, A. M., Zaidman, C. M., Crawford, T. O., Butterfield, R. J., Shieh, P. B., Tennekoon, G., Brandsema, J. F., Iannaccone, S. T., Shoffner, J., Kavanagh, S., Macek, T. A., & Tauscher-Wisniewski, S. (2023). Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG). Journal of Neuromuscular Diseases, 10(3), 389–404. https://doi.org/10.3233/JND-221560

Chicago

Finkel, Richard S., Basil T. Darras, Jerry R. Mendell, John W. Day, Nancy L. Kuntz, Anne M. Connolly, Craig M. Zaidman, et al. 2023. “Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).” Journal of Neuromuscular Diseases 10 (3): 389–404. doi:10.3233/JND-221560.